Trump, RFK Jr. and Dr. Oz unveil major Medicare deal to cover FDA-approved weight-loss drugs
Donald Trump, HHS Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz on Nov. 6, 2025 announced a Medicare deal to expand coverage of FDA-approved weight-loss drugs, aiming to curb obesity in seniors and lower long-term Medicare costs.
- Who: Announced by President Donald Trump, HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz, according to a Fox News report.
- What: Medicare will cover FDA-approved weight-loss medications for eligible beneficiaries, pending CMS review and final eligibility rules.
- Why it matters: Officials say the move could prevent chronic illnesses linked to obesity — such as type 2 diabetes and heart disease — and lower Medicare spending long term.
- Unknowns: Exact eligibility criteria, covered drug list, cost-sharing and implementation timing have not yet been published.
Background and what was announced
In a joint presentation on Nov. 6, 2025, the president, the HHS secretary and the CMS administrator framed the change as a major policy reversal from Medicare’s historical reluctance to pay for weight-loss medications due to past safety concerns and cost. The administration said Medicare will cover prescription weight-loss drugs that have received approval from the U.S. Food and Drug Administration, but implementation will occur only after CMS completes further reviews and sets eligibility guidelines. The initial report was covered by a Fox News report.
Administration rationale and projected savings
Administration officials emphasized rising obesity rates among older Americans have increased spending on diabetes, heart disease and related conditions. They argued that early pharmaceutical intervention, combined with education and physician oversight, could prevent costly illnesses and reduce Medicare expenditures over time. The claim that expanded drug coverage will lower overall Medicare spending was presented as a central justification during the rollout.
“Expanded access to FDA-approved therapies, when paired with proper clinical oversight, can reduce chronic disease and save Medicare money over time,” officials said during the announcement.
Public health campaign and physician outreach
The agreement includes a public health information campaign aimed at both providers and beneficiaries. CMS will lead clinician education on prescribing criteria, monitoring requirements and integration of drug therapy with counseling and lifestyle interventions. Officials said the educational component is designed to reduce inappropriate prescribing and ensure medications are used only when clinically appropriate.
What’s not yet known
Reports to date do not include a complete list of covered medications, precise eligibility rules (such as BMI thresholds or comorbidity considerations), cost-sharing details, or how coverage will be coordinated between traditional Medicare and Medicare Advantage plans. The administration stated that many specifics will be developed after further review; at the time of the announcement public-facing operational documents were not posted alongside the initial release, according to a Fox News report.
Potential policy debates ahead
Experts and watchdogs will likely probe areas including:
- Program cost: Whether long-term savings materialize depends on prevention effectiveness and drug prices.
- Pharmaceutical influence: The role of industry lobbying and negotiation of drug prices under Medicare.
- Clinical safety: Long-term safety of these medications for older populations.
- Eligibility equity: Setting standards that balance access with appropriate oversight.
Medicare weight loss drug coverage: practical questions for beneficiaries
Beneficiaries and families will seek clear guidance. Key practical questions include:
- Which specific FDA-approved drugs will be covered?
- What BMI or comorbidity thresholds will determine eligibility?
- Will coverage include follow-up monitoring and counseling, or only medication?
- How will coverage differ between fee-for-service Medicare and Medicare Advantage?
CMS and local providers have said more guidance will follow as the agency develops implementation rules.
Implications for Fresno, California
Economic impact
If Medicare begins covering FDA-approved weight-loss drugs, Fresno’s hospitals and safety-net clinics could see changes in care patterns. Fresno County has a large Medicare population and many residents with chronic conditions linked to obesity. While long-term reductions in hospital admissions for diabetes and heart disease are possible, near-term prescription spending for providers and payers could increase. Local systems will watch for CMS guidance on reimbursement and formularies to plan budgets and staffing.
Political consequences
Locally, the Medicare deal may shift conversations among elected officials and health administrators in the Central Valley. Moderate voters in Fresno prioritize access and cost control; local leaders will evaluate whether the program improves senior health outcomes, reduces emergency visits and lowers long-term public costs. Federal direction on Medicare policy will also factor into upcoming local and state political debates.
Social effects
For many Fresno families, access to effective weight-management tools could reduce caregiving burdens and improve seniors’ quality of life. However, advocates may express concern about dependence on medication without robust support for nutrition, physical activity and chronic disease management — services already strained in many clinics. CMS’s public information campaign will need to reach Spanish-speaking and other underserved communities to be effective.
Cultural relevance
Fresno’s dietary patterns, work demands and economic stressors shape health outcomes. Any federal expansion of access should be sensitive to local cultural values around food, family caregiving and prevention. Messaging that pairs medication with lifestyle support and community resources is more likely to be effective in Fresno’s diverse neighborhoods.
Practical applications for patients and providers
- Providers: Prepare to review forthcoming CMS and HHS guidance on eligibility and prescribing protocols.
- Pharmacists and clinics: Plan inventory and counseling services in anticipation of increased demand.
- Beneficiaries: Consult primary care providers about potential appropriateness once eligibility rules are released.
- Community groups: Develop outreach to explain benefits and risks, especially for older adults with multiple conditions.
Next steps for the region
Local health leaders will monitor CMS guidance and work with state Medicare counselors and community clinics to translate federal rules into actionable care plans. Until formal eligibility criteria and coverage rules are published, providers and beneficiaries in Fresno should prepare for potential demand increases while awaiting CMS’s operational framework.
Source and attribution
This account is based on reporting by Fox News on Nov. 6, 2025. The announcement and statements were delivered by President Donald Trump, HHS Secretary Robert F. Kennedy Jr., and CMS Administrator Dr. Mehmet Oz, as noted in that report.
Original source: Fox News video
